IPO Profile

Anchiano Therapeutics Ltd. (ANCN)

Offer Price
Offer Size
3-Year Outlook
First Day Turnover


We are a clinical-stage biotechnology company committed to engineering a targeted gene therapy to improve the standard of care for early-stage bladder cancer. We have discovered and are developing a biologic agent, inodiftagene, that we believe can deliver a new treatment to patients who have options that are limited in effectiveness and problematic in toxicity. Bladder cancer is a disease that typically causes symptoms early in its course and consequently presents the patient and the treating physician with an opportunity to gain control of the malignancy. However, the limitations of existing therapies, developed in the 1970s, often result in a prolonged series of unsuccessful treatments that can end in the radical removal of the bladder.

Investors Pre-IPO Holdings (%)
Google Ventures 30
Intel Ventures 20
Patricoff Ventures 5
Kleiner Perkins 18

Deal Highlights

Deal Tracker

Filing Date   07 Feb, 2019
Price Date   12 Feb, 2019
Offer Price $11.50
Offer Size 2M
Look Up Expiry Date   12 Aug, 2019
Earnings Release Date   Nov 1, 2018